No Data
Premium Stocks News = Pollen allergy-related, wood Stocks and other "new faces" stand out.
The cold of winter has peaked, and temperatures are rising nationwide. A concern with the arrival of spring is cedar pollen allergy. This season's dispersal is expected to be high, which may expand the market for mitigation measures. Additionally, the government indicated last year a policy to reduce cedar plantations by 20% over ten years, which is becoming a clue for selection in timber-related stocks. <Promoting Cedar Logging> On the 26th, temperatures rose nationwide, changing from the previous week to a mild climate. According to the Japan Meteorological Agency, from March to May, northern and eastern Japan.
Individual stock information.
FanPep <4881.T> dropped significantly for the fourth consecutive day. A third-party allotment of the 12th subscription rights (with exercise price adjustment clause) will be issued with SBI Securities as the allottee. The allotment date is March 10, with an issue quantity of 80,000 units (potential shares of 8 million shares), and total issuance value of 3.6 million yen. The raised funds of 1.1936 billion yen will be used for expenses related to the phase 1 clinical trial of "FPP004X" being developed for hay fever as the targeted disease. Rentrack <6045.T> had a consolidated revenue of 315 million yen for January.
Fanpep --- Clinical trial of the allergy Vaccine conducted.
Fanpeep <4881> announced on the 21st that it will conduct clinical trials for an allergy vaccine (antibody-inducing peptide FPP004X) for pollen allergy, known as a national disease. The antibody-inducing peptide FPP004X is an allergy vaccine expected to have therapeutic effects by inducing the production of antibodies against IgE in the body. FPP004X is expected to provide a sustained effect against allergies as it induces immune cells to produce anti-IgE antibodies for a certain period. This characteristic is...
Stocks that moved or were traded in the first half of the session.
*Mitsubishi Corporation <8058> 2594.5 +214 Expectations of increased purchases by Mr. Buffett lead major trading companies to buy first. *Marubeni Corporation <8002> 2468 +178.5 Mr. Buffett's letter to investors is regarded as material. *Itochu Corporation <8001> 6550 +409 Major general trading companies show Mr. Buffett's willingness to increase purchases. *Sumitomo Corporation <8053> 3440 +196 Following hints of Mr. Buffett raising his shareholding limit. *Nexela Pharma <4565> 887 +
Fanpepp --- In the fiscal year ending December 2024, research and development will be advanced focusing on antibody-inducing peptide projects and functional peptides.
Fanpep Co., Ltd. <4881> announced its consolidated financial results for the fiscal year ending December 2024 on the 12th. Revenue was 0.006 billion yen (compared to 0 billion yen in the previous period), operating loss was 0.901 billion yen (compared to 0.994 billion yen in loss), ordinary loss was 0.896 billion yen (compared to 0.94 billion yen in loss), and net loss attributable to the Shareholder for the current period was 0.889 billion yen (compared to 0.933 billion yen in loss). In the antibody-inducing peptide project, the antibody-inducing peptide "FPP003" (target protein: IL-17A) is discussed.
Fanpep - Submission of the clinical trial plan for the start of the allergy Vaccine clinical trial.
Fanpep <4881> announced on the 12th that it has submitted the clinical trial plan for the allergy Vaccine (antibody-inducing peptide FPP004X) being developed for allergic rhinitis to the Pharmaceuticals and Medical Devices Agency (PMDA). The Phase 1 clinical trial is scheduled to begin as soon as the PMDA completes its necessary investigation. The antibody-inducing peptide FPP004X induces the production of antibodies against IgE (Immunoglobulin E) in the body to treat.